Need A G, Horowitz M, Morris H A, Walker C J, Nordin B E
Division of Clinical Chemistry, Institute of Medical and Veterinary Science, Adelaide, South Australia.
Clin Orthop Relat Res. 1987 Dec(225):273-8.
Forearm bone mineral content (BMC) was measured sequentially on and off anabolic steroid therapy in 52 postmenopausal women with osteoporosis. The steroid used was nandrolone decanoate in a dose of 50 mg every two weeks by intramuscular injection. In 16 of the patients nandrolone was given first (for 6.2 +/- 0.6 months) followed by a control period (6.1 +/- 1.0 months) and in 36 there was an initial control period (9.5 +/- 1.1 months) followed by nandrolone (for 5.8 +/- 0.4 months). Any other therapy was continued unchanged during both treatment and control periods. There was a significant rise in BMC on nandrolone (p less than 0.001) and a nonsignificant fall in BMC off nandrolone. The difference between the rates of change on and off nandrolone was highly significant (+53 vs. -7 mg/cm/year; p less than 0.001).
对52名患有骨质疏松症的绝经后女性，在接受合成代谢类固醇治疗期间及停药后，依次测量其前臂骨矿物质含量（BMC）。使用的类固醇为癸酸诺龙，剂量为每两周50毫克，通过肌肉注射给药。16名患者先接受诺龙治疗（6.2±0.6个月），随后进入对照期（6.1±1.0个月）；36名患者先有一个初始对照期（9.5±1.1个月），随后接受诺龙治疗（5.8±0.4个月）。在治疗期和对照期，任何其他治疗均维持不变。接受诺龙治疗期间，BMC显著升高（p<0.001），停药后BMC有非显著性下降。诺龙治疗期间与停药后的变化率差异非常显著（分别为+53与-7毫克/厘米/年；p<0.001）。
